Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06056895 · ClinicalTrials.gov registry record · Phase 2

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

A Phase 2 study of Merkel Cell Carcinoma and Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, sponsored by University of Washington.

Active
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT06056895 is a Phase 2 study of Merkel Cell Carcinoma and Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 12 participants, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06056895, a Phase 2 study of Merkel Cell Carcinoma and Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This phase II trial tests how well a combination of three immunotherapy drugs work for patients with Merkel cell carcinoma that has spread to lymph nodes and/or distant parts of the body and cannot be treated with surgery (advanced or metastatic MCC) and grew despite prior PD-(L)1 therapy. The three drugs INCMGA00012 (retifanlimab, anti-PD-1), INCAGN02385 (tuparstobart, anti-LAG-3), and INCAGN02390 (verzistobart, anti-TIM-3) are monoclonal antibodies given periodically via IV to reactivate the body's immune system to attack the cancer. This combination may stop tumor growth if tumors have grown despite anti-PD-(L)1 therapy alone.

Conditions Studied

Merkel Cell Carcinoma Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 Clinical Stage IV Merkel Cell Carcinoma AJCC v8

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • PROCEDURE Magnetic Resonance Imaging
  • BIOLOGICAL Retifanlimab

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-11-08
Est. Completion 2027-04-30
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06056895

The ClinicalTrials.gov registry entry for NCT06056895 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (76% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06056895 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06056895 about?

NCT06056895 is a clinical study titled "Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma". This phase II trial tests how well a combination of three immunotherapy drugs work for patients with Merkel cell carcinoma that has spread to lymph nodes and/or distant parts of the body and cannot be treated with surgery (advanced or metastatic MCC) and grew despite prior PD-(L)1 therapy. The three...

What is the current status of trial NCT06056895?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-11-08. Estimated completion is 2027-04-30.

What conditions does trial NCT06056895 study?

This clinical trial studies the following conditions: Merkel Cell Carcinoma, Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8.

What interventions are being tested in trial NCT06056895?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Retifanlimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06056895?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06056895 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Merkel Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Merkel Cell Carcinoma

All registered trials for this condition

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.